Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical’s CEO will meet investors and present at two New York conferences in September 2026, with one session webcast for 30 days.

Rhea-AI Summary

Journey Medical Corporation (DERM)/b) will participate in two investor conferences in September 2026.Co-Founder, President and CEO Claude Maraoui is scheduled for the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026, in New York City in a 1x1 meetings format. He is also scheduled for the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 10:00 a.m. ET, also in New York City, featuring a presentation and 1x1 meetings.

A webcast of the H.C. Wainwright presentation will be available on the News and Events page of the Investors section of Journey Medical’s website for approximately 30 days after the meeting.

Key Terms

fda-approved, securities exchange act

2 terms

fda-approved regulatory

"FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

securities exchange act regulatory

"common stock is registered under the Securities Exchange Act of 1934"

A securities exchange act is a law that sets the rules for how public securities markets operate, requiring regular disclosure by traded companies, policing insider trading, and overseeing market intermediaries. Think of it as a rulebook and referee combined: it forces companies to share financial and material information and gives regulators tools to investigate and punish unfair behavior, which helps investors make informed decisions and reduces the chance of fraud or market manipulation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright 28th Annual Global Investment Conference
Date and Time: Monday, September 14, 2026, at 10:00 a.m. ET
Location: New York City
Format: Presentation and 1x1 Meetings

A webcast of the Company’s presentation at H.C. Wainwright will be available on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and the company files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FAQ

How can investors access Journey Medical’s presentation at the H.C. Wainwright conference?

A webcast of Journey Medical’s presentation at the H.C. Wainwright 28th Annual Global Investment Conference will be available on the News and Events page of the Investors section of the company’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.

What type of participation will Journey Medical have at the Lake Street BIG10 conference?

At the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on September 10, 2026, in New York City, Journey Medical’s CEO Claude Maraoui will participate in a 1x1 meetings format.

What is Journey Medical Corporation’s primary business focus?

Journey Medical is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions.